N-(Piperazinylalkoxyphenyl)-N'phenylalkylurea derivatives as ACAT inhibitors for the treatment of atheroschlerosis
申请人:MITSUBISHI CHEMICAL CORPORATION
公开号:EP0773218A1
公开(公告)日:1997-05-14
A compound represented by formula (I) and a salt thereof, and a hydrate and solvate thereof:
wherein R1, R2 and R3 represent independently, for example, hydrogen atom, hydroxyl group, or C1-3 alkoxy group; R4 represents, for example, C1-7 alkyl group or C3-7 cycloalkyl group; R5 and R6 represent independently, for example, hydrogen atom or C1-3 alkyl group; Y represents C1-3 alkyl group, a heterocyclic group containing 1 to 4 nitrogen atoms and 5 or 6 ring-membered atoms, or C6-10 aryl group; k represents an integer of 1 to 3; and ℓ represents an integer of 2 to 4. These urea compounds have excellent inhibitory activities against ACAT and are useful as active ingredients of medicines for preventive and/or therapeutic treatment of hyperlipemia and atherosclerosis.
由式(I)代表的化合物及其盐,以及其水合物和溶液:
其中 R1、R2 和 R3 分别代表氢原子、羟基或 C1-3 烷氧基;R4 代表 C1-7 烷基或 C3-7 环烷基;R5 和 R6 分别代表氢原子或 C1-3 烷基;Y 代表 C1-3 烷基、含有 1 至 4 个氮原子和 5 或 6 个环状原子的杂环基团或 C6-10 芳基;k 代表 1 至 3 的整数;ℓ 代表 2 至 4 的整数。这些脲化合物对 ACAT 具有极佳的抑制活性,可用作预防和/或治疗高脂血症和动脉粥样硬化的药物活性成分。